2
Claims by status
Every claim in one place, with a review queue so nothing lapses and a clear view of what a label update touches.
All claims
| ID | Claim text | Status | Expiry | Risk info | Msg strength* | Used in |
|---|---|---|---|---|---|---|
| C-001 | [Outcome A] reached by Week 12 in [Study 1] | Approved | 15 Mar 2027 | ISI-01 | 82 | 4 |
| C-002 | [Outcome B] sustained through Week 52 in [Study 1] | Approved | 20 Jan 2027 | ISI-01 | 76 | 2 |
| C-003 | Once-daily oral dosing, with or without food | Approved | 30 Jun 2027 | ISI-01 | 71 | 3 |
| C-004 | [Outcome C] in patients with [subgroup] in [Study 2] | Expiring <60d | 18 Nov 2026 | ISI-02 | 68 | 1 |
| C-005 | [Outcome A] reached by Week 4 in [Study 2] | Expiring <60d | 1 Dec 2026 | ISI-02 | 79 | 1 |
| C-006 | [Outcome D] maintained through Week 104 in [Study 3] extension | Modified | 10 Feb 2027 | ISI-01 | 64 | 1 |
| C-007 | No [lab monitoring] required at treatment start | Modified | 10 Feb 2027 | ISI-01 | 59 | 1 |
| C-008 | No dose adjustment needed for [population] | Modified | 10 Feb 2027 | ISI-01 | 55 | 1 |
| C-009 | [Outcome E] by Week 8 in [Study 4] | New | (not set) | ISI-01 | 58 | 1 |
| C-010 | Lower [event] rate vs [comparator] in [Study 4] | New | (not set) | ISI-01 | 61 | 1 |
| C-011 | [Outcome F] in patients previously treated with [drug class] | Prior approval expired | 30 Sept 2026 | ISI-01 | 66 | 1 |
| C-012 | Preferred option per [guideline body] | FDA removed | 14 Aug 2026 | ISI-01 | 40 | 0 |
* Score from message testing (placeholder)
Review queue (7)
Expiring in under 60 days is a review queue so claims are re-reviewed before they lapse.
- C-004[Outcome C] in patients with [subgroup] in [Study 2]Expiring <60d37 days to expiry
- C-005[Outcome A] reached by Week 4 in [Study 2]Expiring <60d50 days to expiry
- C-006[Outcome D] maintained through Week 104 in [Study 3] extensionModified
- C-007No [lab monitoring] required at treatment startModified
- C-008No dose adjustment needed for [population]Modified
- C-009[Outcome E] by Week 8 in [Study 4]New
- C-010Lower [event] rate vs [comparator] in [Study 4]New
Label update impact · LBL-2026-01 Brand X label update
Effective 5 Oct 2026 · Trigger: Label change · Applied
- Section 14
New 104-week extension data
Affects C-006
- Section 5
New lab monitoring requirement
Affects C-007
- Section 2
Revised dosing statement for [population]
Affects C-008
Affected claims
Affected pieces
Before → after
Approved6 3
Modified0 3
How statuses move
ReviewMedical, Regulatory, Legal — all three review customer-facing contentApproved
- Claim or label change Modified review queue
- 60 days before expiry Expiring <60d
- Expiry date passes Prior approval expired
- FDA action or removal letter FDA removed
The marketing ops coordinator moves each status. This is a working assumption.